Recent Bibliometrics of the Journal and Thank You to Our Reviewers

Zbigniew K. Wszolek[1], Łukasz Stolarczyk[2], Jarosław Sławek[3]

[1]Co-Editor-in-Chief, Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, United States

[2]Journal Administrator, Via Medica, Gdansk, Poland

[3]Co-Editor-in-Chief, Department of Neurological-Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland

Both Clarivate™ and Elsevier recently released their journal bibliometric measurements. We are incredibly pleased to report that the Impact Factor (IF) reported by Clarivate™ of the Neurologia i Neurochirurgia Polska (also known as Polish Journal of Neurology and Neurosurgery, PJNNS) remains stable at 2.9 (Fig. 1, bars). In post-COVID-19 times, many highly cited journals were not able to maintain their IF score. The IF score for 2023 was calculated by taking the number of citations in 2023 of all items published in PJNNS in 2021 and 2022, including editorial notes, invited editorials, invited review articles, review articles, research papers, short communications, and letters to the editors and dividing that number by the total number of research papers, short communications, invited reviews, and review articles published in 2021 and 2022 years. However, the PJNNS journal has moved from Q3 level in 2022 to Q2 level in 2023 (Fig. 1, line). This is an important achievement. Currently, PJNNS is ranked 99/277 in Web of Science™ category, "Clinical Neurology".

Elsevier's Scopus CiteScore™ (CS) of PJNNS has risen from 3.4 in 2022 to 4.2 in 2023 (Fig. 2). Scopus CS measures the bibliometric status of the journal differently than Clarivate™ IF. Calculations of current CS include a period of 4 years, including citations of the calculation's year and count all published items (ie, editorial notes, invited editorials, invited review articles, review articles, research papers, short communications, and letters to the editors). The steady increase of PJNNS's Scopus CS is very encouraging.

Moreover, the PJNNS Immediacy Index (ImI) calculated by Clarivate™ has also substantially improved (Fig. 3). ImI counts the citations to the journal's published items in the current year. Thus, it represents the bibliometric measure of relevance of published articles in the same year. The ImI of PJNNS has systematically increased from 0.3 in 2019 to 1.4 in 2023.


Figure 1. PJNNS's Impact Factor (IF) Trend. Despite the same value of IF for 2022 and 2023 (IF = 2.9, bars), PJNNS has achieved higher ranking in journal IF (JIF) assessment (line). PJNNS has moved from Q3 to Q2 (JIF percetile rose from 45.5 in 2022 to 64.4 in 2023). Source: JCR Edition 2024 by Clarivate Analytics

Table 1 presents the 11 most cited articles in 2021 and 2022 that contributed to PJNNS's 2023 IF (3 had an equal number of citations). Seven were research papers and 4 were review articles. They dealt with a wide-spectrum of neurologic conditions, including stroke, neurologic manifestations of COVID-19, and movement disorders.

The status of PJNNS would never be possible without the contribution of authors and tireless work of the Journal's peer reviewers. The editors of PJNNS and the administrative staff of our Journal's publisher, Via Medica, are incredibly grateful to our reviewers for their generous commitment to the Journal. The editors truly understand the effort and time required to review the submitted articles. Thus, as a small

Figure 2. PJNNS's Elsevier Scopus CiteScore™ (CS) Trend. CS represents a key bibliometric parameter measuring the journal's standing and is calculated from the Scopus database. CS has demonstrated a systematic growth for PJNNS. Current CS is based on the number of citations received by the journal in the last 4 years (including the calculation year) divided by the number of documents published (all items) in the journal in those 4 years. Based on this measure, PJNNS has been ranked 125/551 (77th percentile) in the Scopus category, "Medicine/Surgery", and 187/400 (53rd percentile) in the category, "Medicine/Neurology (Clinical)". Source: Data from Scopus database

token of appreciation, we present here a list of our dedicated reviewers (Table 2). We highlighted in green those reviewers who provided 3 or more reviews in 2023.

Figure 3. PJNNS's Immediacy Index (ImI) Trend. ImI counts all citations in the current year to the journal's content in this same year. Journals that have a high ImI attract citations rapidly. Source: JCR Edition 2024 by Clarivate Analytics

Table 1. Eleven most cited manuscripts published in PJNNS that contributed to calculation of 2023 Journal Impact Factor

First author	Title	Year published	Type	Reference
Madetko N. et al.	Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns	2022	Research Paper	[1]
Bratosiewicz-Wasik J.	Neuro-COVID-19: an insidious virus in action	2022	Review	[2]
Gueye T. et al.	Early post-stroke rehabilitation for upper limb motor function using virtual reality and exoskeleton: equally efficient in older patients	2021	Research Paper	[3]
Peycheva M. et al.	The role of fibrinogen in acute ischaemic stroke	2021	Research Paper	[4]
Alster P. et al.	Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)	2021	Research Paper	[5]
Czarnowska A. et al.	Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience	2021	Research Paper	[6]
Przytula F. et al.	Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome	2021	Research Paper	[7]
Wnuk M. et al.	Neurological symptoms in hospitalized patients with COVID-19 and their association with in-hospital mortality	2021	Research Paper	[8]
Nojszewska M. et al.	COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society*	2021	Review	[9]
Milanowski Ł. et al.	Genetics of Parkinson's disease in the Polish population*	2021	Review	[10]
Mazurkiewicz-Bełdzińska M. et al.	Use of cannabidiol in the treatment of epilepsy*	2022	Review	[11]

*These manuscripts had equal number of citations

Table 2. Alphabetical list of PJNNS reviewers in 2023. Names of reviewers who provided three or more reviews appear in green

First name	Last name	First name	Last name
Monika	Adamczyk-Sowa	Michał	Karliński
Piotr	Alster	Radosław	Kaźmierski
Wojciech	Ambrosius	Magdalena	Koszewicz
Mohamed	Arnaout	Tomasz	Kotwicki
Yasuhiko	Baba	Grzegorz	Kozera
Anna	Barczak	Ewa	Krzystanek
Halina	Bartosik-Psujek	Wirginia	Krzyściak
Joanna	Bielewicz	Alina	Kułakowska
Magdalena	Boczarska-Jedynak	Iwona	Kurkowska-Jastrzębska
Robert	Bonek	Anetta	Lasek-Bal
Magdalena	Bosak	Michelle	Lin
Daniel	Broderick	Marta	Lipowska
Waldemar	Brola	Alfonso S.	Lopez Chiriboga
Askiel	Bruno	Tomasz	Lyson
Sławomir	Budrewicz	Beata	Łabuz-Roszak
Krzysztof A.	Bujarski	Dariusz	Łątka
Kamil	Chwojnicki	Tomasz	Mandat
Victor	Constantinescu	Marek	Mandera
Arthur	Cukiert	Zenon	Mariak
Jeremy	Cutsforth-Gregory	Iris	Marin Collazo
Elliot	Dimberg	James F.	Meschia
Tomas	Dobrocky	Sławomir	Michalak
Brynn	Dredla	Erik	Middlebrooks
Jarosław	Dulski	Grzegorz	Miękisiak
Judith	Dunmore	Łukasz	Milanowski
Stephen	English	David	Miller
Olga	Fermo	Dagmara	Mirowska-Guzel
Andrzej	Friedman	Karthik	Muthusamy
Shinsuke	Fujioka	Eric W.	Nottmeier
Tomasz	Gabryelewicz	Julia	Nowak
Dariusz	Gąsecki	Simy	Parikh
Neil	Graff-Radford	Mikolaj	Pawlak
Mario	Habek	Jukka	Peltola
Michael	Heckman	Ronald	Pfeiffer
Maria	Hoeltzenbein	Anna	Pokryszko-Dragan
Josephine	Huang	Mercedes	Prudencio
Lauren	Jackson	Maciej	Racinowski
Jeremiasz	Jagieła	Maciej	Radek
Sergiusz	Jóźwiak	Vedantam	Rajshekhar
Alicja	Kalinowska-Łyszczarz	Jill	Rau
Karolina	Kania	Konrad	Rejdak
Katarzyna	Kapica-Topczewska	Bertold	Renner
Bartosz	Karaszewski	Maria	Respondek-Liberska
		Joao	Ricardo

→

Table 2. cont. Alphabetical list of PJNNS reviewers in 2023. Names of reviewers who provided three or more reviews appear in green

First name	Last name	First name	Last name
Hector	Robles	Jacek	Staszewski
Radosław	Rola	Barbara	Steinborn
Jacek	Rożniecki	Piotr	Szczudlik
Monika	Rudzińska-Bar	Jacek	Szczygielski
Iwona	Sarzyńska-Długosz	Stanisław	Szlufik
Katarzyna	Sawczyńska	Tomasz	Szmuda
Michał	Schinwelski	Paweł	Tacik
Thomas G.	Schreiner	Philip	Tipton
Zbigniew	Serafin	Ryan	Uitti
Mariusz	Siemiński	Marta	Waliszewska-Prosół
Halina	Sienkiewicz-Jarosz	Lindsy	Williams
Joseph	Sirven	Joanna	Wojczal
Emilia	Sitek	Zyta	Wojszel
Joanna	Siuda	Sevil	Yasar
Matej	Skorvanek	Joanna	Zajkowska
Agnieszka	Słowik	Beata	Zakrzewska-Pniewska
Jerzy	Słowiński	Marta	Zawadzka
Piotr	Sobolewski	Daniel	Zielonka
Michał	Sobstyl	Jarosław	Zygierewicz
Alexandra E.	Soto Pina	Wioletta	Żukowicz
Mariusz	Stasiołek	Kamila	Żur-Wyrozumska

References

1. Madetko N, Migda B, Alster P, et al. Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns. Neurol Neurochir Pol. 2022; 56(2): 148–155, doi: 10.5603/PJNNS.a2022.0014, indexed in Pubmed: 35118638.
2. Bratosiewicz-Wąsik J. Neuro-COVID-19: an insidious virus in action. Neurol Neurochir Pol. 2022; 56(1): 48–60, doi: 10.5603/PJNNS.a2021.0072, indexed in Pubmed: 34642927.
3. Gueye T, Dedkova M, Rogalewicz V, et al. Early post-stroke rehabilitation for upper limb motor function using virtual reality and exoskeleton: equally efficient in older patients. Neurol Neurochir Pol. 2021; 55(1): 91–96, doi: 10.5603/PJNNS.a2020.0096, indexed in Pubmed: 33314016.
4. Peycheva M, Deneva T, Zahariev Z. The role of fibrinogen in acute ischaemic stroke. Neurologia i Neurochirurgia Polska. 2021; 55(1): 74–80, doi: 10.5603/pjnns.a2020.0094.
5. Alster P, Madetko N, Friedman A. Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS). Neurol Neurochir Pol. 2021; 55(1): 97–101, doi: 10.5603/PJNNS.a2020.0097, indexed in Pubmed: 33315235.
6. Czarnowska A, Brola W, Zajkowska O, et al. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience. Neurologia i Neurochirurgia Polska. 2021; 55(2): 212–222, doi: 10.5603/pjnns.a2021.0031.
7. Przytuła F, Błądek S, Sławek J. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. Neurologia i Neurochirurgia Polska. 2021; 55(3): 310–313, doi: 10.5603/pjnns.a2021.0036.
8. Wnuk M, Sawczyńska K, Kęsek T, et al. Neurological symptoms in hospitalised patients with COVID-19 and their association with in-hospital mortality. Neurologia i Neurochirurgia Polska. 2021; 55(3): 314–321, doi: 10.5603/pjnns.a2021.0039.
9. Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol. 2021; 55(1): 8–11, doi: 10.5603/PJNNS.a2021.0016, indexed in Pubmed: 33555604.
10. Milanowski Ł, Ross O, Friedman A, et al. Genetics of Parkinson's disease in the Polish population. Neurologia i Neurochirurgia Polska. 2021; 55(3): 241–252, doi: 10.5603/pjnns.a2021.0013.
11. Mazurkiewicz-Bełdzińska M, Zawadzka M. Use of cannabidiol in the treatment of epilepsy. Neurol Neurochir Pol. 2022; 56(1): 14–20, doi: 10.5603/PJNNS.a2022.0020, indexed in Pubmed: 35211946.